Investor Relations | Forty Seven, Inc. Forty Seven is a clinical-stage immuno-oncology company focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer Forty Seven focus its efforts on targeting the CD47 pathway as a way to engage macrophages in fighting tumors
Stock Quote Chart | Forty Seven, Inc. The Investor Relations website contains information about Forty Seven, Inc 's business for stockholders, potential investors, and financial analysts
FORTY SEVEN, INC. Forty Seven Inc Condensed Balance Sheets (I n t h ou s an ds ) September 30, 2019 December 31, 2018 (Unaudited) (1) Assets Current assets: Cash and cash equivalents $ 31,783 $ 10,837 Short-term investments 134,959 128,186 Prepaid expenses and other current assets 10,583 6,835
FORTY SEVEN, INC. On March 2, 2020, Forty Seven, Inc , a Delaware corporation (the “C om pan y” or “F or t y S e v e n”), issued a press release announcing the entry into an Agreement and Plan of Merger (the “M e r ge r A gr e e m e n t ”), by and among the Company, Gilead Sciences, Inc , a Delaware corporation (“P ar e n t ” or
Investor FAQs | Forty Seven, Inc. Forty Seven does not currently have a direct stock purchase plan The Company’s common stock can be purchased by contacting a securities broker of your choice Does Forty Seven have a dividend reinvestment program?
Forty Seven Inc. to Present at the 2018 BIO CEO Investor Conference . . . Forty Seven Inc is a clinical-stage immuno-oncology company that is developing therapies licensed from Stanford University targeting cancer immune evasion pathways The lead program Hu5F9-G4 is a monoclonal antibody against the CD47 receptor, a "don't eat me" signal that cancer cells commandeer to avoid being ingested by macrophages
Forty Seven to Present at Upcoming Investor Conferences in February . . . MENLO PARK, Calif , Feb 06, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc (Nasdaq:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced its participation in the following upcoming investor conferences:
Historic Price Lookup - Forty Seven, Inc. Date Requested Closing Price Volume Split Adjustment Factor Open Price Day High Day Low; April 6, 2020: $95 51: 693,725: 1:1: $95 46: $95 52: $95 46: April 7, 2020
Forty Seven Inc. to Present at Canaccord Genuity 39th Annual Growth . . . Forty Seven, Inc is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways based on technology licensed from Stanford University Forty Seven’s lead program, 5F9, is a monoclonal antibody against the CD47 receptor, a “don’t eat me” signal that cancer cells commandeer to avoid
Forty Seven, Inc. Announces Foundational Preclinical Data Supporting . . . MENLO PARK, Calif , Dec 09, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced preclinical proof-of-concept data for its novel all antibody conditioning regimen, comprised of FSI-174, its anti